While KRAS somatic analysis is routinely performed in CRC using targeted NGS panels or comprehensive genomic profiles due to its prognostic and predictive relevance for KRAS‐G12C targeted therapies,28, 29 the use of KRAS‐G12C as a MAP biomarker remains neglected. The gene discussed is KRAS; the disease is colorectal carcinoma.